Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Piracetam | Pramiracetam | |
|---|---|---|
| Category | Nootropics | Nootropics |
| Standard Dose | 1200-4800 mg/day divided into 2-3 doses | 400-1200 mg/day divided into 2-3 doses |
| Timing | With or without food; split doses morning and afternoon to maintain plasma levels | With fat-containing meals (fat-soluble). Morning and early afternoon dosing preferred. |
| Cycle Duration | Cycles of 8-12 weeks on, 4 weeks off; or ongoing with periodic reassessment | Cycles of 8-12 weeks on, 4 weeks off |
| Evidence Level | moderate_human | moderate_human |
Positive allosteric modulator of AMPA receptors, binding at a unique site along the dimer interface to reduce desensitization and deactivation. Inhibits N-type calcium channels at clinically relevant CNS concentrations. Enhances membrane fluidity of neuronal phospholipids and modulates neurotransmission across cholinergic and glutamatergic systems.
1200-4800 mg/day divided into 2-3 doses
With or without food; split doses morning and afternoon to maintain plasma levels
Cycles of 8-12 weeks on, 4 weeks off; or ongoing with periodic reassessment
Potently stimulates high-affinity choline uptake (HACU) in hippocampal synaptosomes, the rate-limiting step in acetylcholine synthesis. This profoundly enhances cholinergic neurotransmission without direct receptor agonism. Approximately 10-30x more potent than piracetam on a per-milligram basis. Does not significantly affect other neurotransmitter systems, making it a highly targeted cholinergic enhancer.
400-1200 mg/day divided into 2-3 doses
With fat-containing meals (fat-soluble). Morning and early afternoon dosing preferred.
Cycles of 8-12 weeks on, 4 weeks off
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →